目的：建立測(cè)定人血漿中人參三醇二琥珀酸酯鈉的液相色譜-質(zhì)譜聯(lián)用法。方法：色譜柱為Shimadzu VP-C₁₈柱（150 mm×2.0 mm，5 μm）； 乙腈-10 mmol/L乙酸銨水溶液（55∶45）為流動(dòng)相，體積流量0.3 mL/min；柱溫40 ℃；內(nèi)標(biāo)物吲達(dá)帕胺。質(zhì)譜條件為電噴霧離子源（ESI），選擇負(fù)離子提取方式檢測(cè)，人參三醇二琥珀酸酯鈉和吲達(dá)帕胺的選擇檢測(cè)離子分別為m/z 675.5（[M-Na+H] ⁺）、m/z 364.1（[M+H] ⁺ ）。結(jié)果：人參三醇二琥珀酸酯鈉線性范圍為0.030 4～101.3 μg/mL，定量下限為0.030 4 μg/mL。準(zhǔn)確度、精密度以及穩(wěn)定性均符合有關(guān)要求。結(jié)論：本方法專屬性強(qiáng)，靈敏度高，適用于人血漿中人參三醇二琥珀酸酯鈉的藥代動(dòng)力學(xué)研究。

Objective: To develop a sensitive and specific LC-MS method for the determination of sodium panaxatriol disuccinate in human plasma. Methods: Separation was carried out on a Shimadzu VP-ODS analytical column (150 mm × 2.0 mm, 5 μm) with a mobile phase of CH₃CN-10 mmol/L ammonium acetate (55:45) at a flow rate of 0.3 mL/min. The internal standard was Indapamide. ESI was applied and operated in negative mode. The ion of monitor: m/z 675.5 (sodium panaxatriol disuccinate), m/z 364.1 (Indapamide). Results: The linear calibration curve was observed in the concentration range of 0.030 4 － 101.3 μg/mL. The lower limit quantification was 0.030 4 μg/mL. The accuracy, precision (intra-day and inter-day), sensitivity and stability (ambient temperature, freeze/thaw, freeze storage) of the method fulfilled the guideline of the analytical validation criteria. Conclusion: The method with specificity is sensitive, rapid and suitable for pharmacokinetics study on sodium panaxatriol disuccinate in human plasma.